African horse sickness virus cDNA and Antigen

African horse sickness virus (AHSV) is a vector-borne virus that affects horses and other equids. This virus is of major importance in equine health and is a major cause of mortality in horses in endemic regions. In order to further understand the transmission and pathology of this virus, cDNA and recombinant antigens have been developed to study the virus and its effects. This product description provides information on the cDNA and recombinant antigen derived from African horse sickness virus, including the properties of the cDNA and antigen, applications, and methods for use.

The genome of African horse sickness virus (AHSV) is a non-segmented, single-stranded, negative-sense RNA virus of the genus Orbivirus in the family Reoviridae. The genome consists of 10 linear double-stranded RNA segments, ranging in size from 0.8 to 4.7 kb. The genome encodes for 13 core proteins, including a polymerase, helicase, capsid proteins, and several other non-structural proteins. AHSV also encodes for two additional proteins, called VP7 and VP2, that are important for viral replication.

Non-structural protein 1 (NS1)
NS1 is a multifunctional protein that is involved in multiple steps of the viral replication cycle. It functions as a capping enzyme for viral mRNAs, promotes the translation of viral proteins, and inhibits host cell gene expression. NS1 also interferes with the host immune response by inhibiting the production of type I interferon.

Non-structural protein 3 (NS3)
NS3 is a serine protease that is responsible for cleaving the viral polyprotein into individual functional proteins. It is a critical component of the viral replication complex and is essential for the formation of viral replication factories.

Non-structural protein NS4
NS4 is a non-essential protein that has been shown to play a role in the modulation of the host immune response. It inhibits the activation of nuclear factor kappa B (NF-kB), a transcription factor that regulates the expression of genes involved in the immune response.

Protein VP6
VP6 is a structural protein that forms the inner capsid of the AHSV virion. It is involved in the packaging of the viral genome and plays a critical role in virus assembly.

Outer capsid protein VP2
VP2 is the major structural protein of the AHSV outer capsid. It is responsible for the induction of neutralizing antibodies and is a major determinant of the virus serotype.

Core protein VP3
VP3 is a structural protein that forms the inner capsid of the AHSV virion. It is involved in the packaging of the viral genome and plays a critical role in virus assembly.

Core protein VP4
VP4 is a minor structural protein that forms the inner capsid of the AHSV virion. It is involved in the packaging of the viral genome and plays a critical role in virus assembly.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

African horse sickness virus (AHSV) cDNA and recombinant antigens can be used for a range of applications, including diagnosis and vaccine development. AHSV cDNA can be used to generate infectious AHSV particles, as well as to express specific antigens for use in ELISA and other immunoassays. Recombinant antigens can also be used to develop subunit vaccines, which are safer and easier to manufacture than traditional live-attenuated vaccines. Additionally, AHSV cDNA and recombinant antigens can be used to generate monoclonal antibodies for use in diagnostic tests.